France ponders off-label Avastin

Share this article:

France is the latest country poised to give the OK to swap Roche's cheaper drug Avastin for the company's pricier eye medication Lucentis. Reuters reports legislators are introducing an amendment to France's social security budget bill that would permit physicians to use Avastin to treat age-related macular degeneration. The amendment's sponsor, Gerard Bapt, says the move could shave around $273 million from annual expenses were doctors to use Avastin, and a vote is due next week.

Italy pulled a similar move last month, and Novartis's reaction is the same as it was then: the company says the off-label use puts patients at risk. Novartis markets the drug in Europe.

“We do not see how reimbursing off-label use for cost reasons in France is justified in the interest of public health,” the company told Reuters Wednesday.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.